Joe Rogan Just Put Big Pharma on Blast… and This Tiny Peptide Company Could Be the Reason Why

Joe Rogan just sounded the alarm on Big Pharma… and the timing couldn’t be more perfect.

And let’s be honest—he’s not wrong.

For decades, pharmaceutical giants have thrived on treating symptoms, not curing anything.¹ Aging, weight gain, mental fog… they’ve convinced us these are just “part of life.”

But behind the curtain, a new class of compounds is quietly redefining what’s possible—compounds that don’t just treat, but optimize.

They’re called peptides, and they’re already being used by billionaire investors, elite athletes, and Hollywood insiders to extend healthspan, accelerate fat loss, boost cognition, and rebuild muscle… with remarkable precision.

3h434j

Peptides are short chains of amino acids that act like biological messengers, instructing the body to heal, regenerate, and optimize itself at the cellular level.

Once reserved for elite athletes and the ultra-wealthy, these compounds are now at the forefront of a longevity revolution—unlocking enhanced performance, faster recovery, better sleep, fat loss, and even biological age reversal.

This isn’t gene editing. It’s not some Silicon Valley pipe dream.

It’s a real, science-backed revolution—one that could soon reshape medicine, wellness, and even longevity itself.

In fact, the global peptide therapeutics market is projected to hit $117.4 billion by 2034.²

And just like Coinbase became the go-to platform for crypto before the first major wave hit…

There’s one company aiming to do the same for peptides. A disruptive biotech startup—quietly backed by Silicon Valley insiders—is about to take this fight mainstream.

This Company is offering investors a rare opportunity to gain early exposure to a breakthrough market with boundless potential.

The company is called Vesalius Longevity Labs.

And we believe they’re at the forefront of potentially one of the biggest biotech shifts we’ll see in our lifetime.

In fact, the best way to understand just how big this could become…

Is to look at what happened when another company transformed access to healthcare—using telemedicine to make treatment faster, easier, and more affordable for consumers — and built a billion-dollar brand in the process.

The “Hims & Hers” of Peptides?

In 2017, a startup called Hims & Hers launched with a bold vision: normalize men’s health treatments by offering fast, discreet access to generics for hair loss and ED — all online.

Their approach?

1. 1. Simplify the process.
  2. Own the customer relationship
  3. Control the supply chain.

By 2021, they were trading on the NYSE.

Today, they’re a $8.09 billion brand with a loyal Gen Z and Millennial customer base.

Take a look at the growth:

graph32b

Source: Google Finance March 25, 2025

From a quiet DTC startup in 2017 to a publicly traded juggernaut with an $8B+ market cap in 2025, Hims has shown what’s possible when you’re early to a massive consumer health trend.

- - 2017: Launched online DTC platform³
  - 2018: Raised $50M Series B (~$500M valuation)⁴
  - 2019: Raised $100M Series C (~$1B valuation)⁵
  - 2020 (Oct): SPAC merger announced ($1.6B valuation)⁶
  - 2021 (Jan): Listed on NYSE (~$2.0B market cap)
  - 2024: Profitable with diversified SKUs (~$1.5B market cap)
  - 2025: Stock surges to $37.04 (March 25, 2025) → Market Cap: $6.2B

That’s a ~279% gain over the past 5 years — and a 5x+ jump in market cap from its 2024 valuation.

Now here’s the exciting part…

While Hims built its business around generic medications…

Vesalius Longevity Labs is targeting a more powerful, scientifically advanced category:

Peptides — biologically active compounds that influence everything from fat loss and muscle gain to sleep, skin, hormone optimization, and cellular repair.

Like Hims, Vesalius Longevity Labs owns the entire pipeline — from telehealth consultations to fulfillment to customer experience.

But unlike Hims, they’re not solving for hair loss or ED.

They’re operating in the longevity space — helping people pursue a longer, healthier life.

And while Hims has already captured Wall Street’s attention…

Vesalius is still under the radar.

That could make right now the ideal time to take notice — before mainstream analysts and institutions catch on.

Why Peptides, Why Now?

Peptides aren’t new. They’ve been used in medicine for over 100 years.

But something big is happening right now.

The global peptide therapeutics market — currently worth $42 billion — is projected to more than double to $117 billion by 2034,⁷ growing at a blistering 10.8% annually.

That’s not hype — that’s hard data.

Unlike traditional treatments, peptides can be biologically targeted, safer, and far more effective at things like repairing muscle tissue, balancing hormones, burning fat, and even reversing aging at the cellular level.

jk23b3

It’s why some of the most powerful people in the world are leaning in.

When a Prince Gets Involved, You Pay Attention

You’re not just looking at a science project here.

This company is backed by HRH Prince Khaled bin Alwaleed Al Saud,⁸ part of the Saudi royal family and one of the most active investors in cutting-edge health tech and sustainability.

Also on board?

Ahmed Alkhoshaibi — CEO of ARADA and top executive at KBW Investments — bringing serious capital markets horsepower.

These aren’t random names.

These are the kinds of people who don’t join just any startup — they place strategic bets on where the future is headed.

And right now?

They’ve placed it on Vesalius Longevity Labs.

But They’re Not Alone…

- - Gary Brecka – Arguably one of the most recognizable figures in biohacking and human optimization today. A massive influencer in the health space.
  - Chris Bumstead (Cbum) – 6x Mr. Olympia. Iconic. With millions of followers, he brings enormous authority in the performance and fitness world.
  - George Kittle – NFL superstar and brand-builder. His presence adds mass-market trust and credibility.

Untitled design 4 1 e1744147613992

But perhaps the clearest signal that peptides are moving from fringe to forefront comes from Dr. Jonathan Kuo, a board-certified anesthesiologist and regenerative medicine expert whose New York-based clinic has quietly become the go-to destination for celebrities and ultra-high-net-worth individuals seeking cutting-edge peptide therapies.

His client roster includes celebrities like Tesla board member Kimbal Musk and NFL legend Troy Aikman—all tapping into peptides for performance, recovery, and age reversal.

Now, Dr. Kuo is working directly with Vesalius Longevity Labs to power his clinic’s peptide supply — a partnership that not only validates Vesalius’ formulations, but places their products directly into the hands of culture-shaping names.

This isn’t theoretical adoption. It’s already happening — quietly, among those with the means to be first.

Top 8 Reasons

This Could Quietly Be One of the Most Compelling Early-Stage Biotech Opportunities

First-Mover in a $117B+ Peptide Market: Vesalius Longevity Labs will be the first publicly traded company focused exclusively on peptides and bioregulators—two of the most exciting sectors in health and longevity. The global peptide therapeutics market is expected to exceed $117 billion by 2034,⁹ giving Vesalius a significant head start in a highly fragmented industry ripe for consolidation.

Game-Changing B2D Model: Unlike grey-market vendors, Vesalius operates a business-to-doctor (B2D) model that ensures regulatory compliance, clinical integrity, and global scalability. Their platform offers healthcare professionals a one-stop solution with premium peptides, transparent sourcing, and simplified logistics.

Elite Advisors & Celebrity Backing: Vesalius is endorsed by industry titans and cultural icons, including Gary Brecka, Ben Greenfield, Dr. Matt Cook, and Dr. Jonathan Kuo. Strategic ambassadors like Chris Bumstead (Cbum) and NFL superstar George Kittle bring mass-market appeal and trust.

Global Distribution + Proprietary Tech: Vesalius Longevity Labs is building a proprietary ordering and distribution system, allowing for seamless global delivery to medical professionals. With reach across the US, Europe, and the Middle East—and plans for APAC expansion—they are positioned for international dominance.

Deep Pipeline & Product Differentiation: Their portfolio includes injectables, patches, nasal sprays, oral peptides, hydrogel technology, and topical formulations—each designed to help doctors address real-world pain points like compliance, convenience, and delivery effectiveness. Products range from performance-enhancing compounds like BPC-157 and MOTS-C to cognitive peptides.

M&A-Driven Growth Strategy: Following a reverse takeover with Sweet Earth Holdings, Vesalius Longevity Labs will be aggressively pursuing a roll-up strategy in a fragmented market. Their roadmap includes further acquisitions of compliant operators to rapidly build market share.

Medical-Grade Science Meets Lifestyle Wellness: With a hybrid B2D and B2C approach, Vesalius Longevity Labs bridges clinical-grade science with wellness consumerization. From high-end clinics to a direct-to-consumer platform powered by Celia, the company is integrating longevity products into mainstream health consciousness.

Experienced Operators with PE-Backed Exits: Led by CEO Kevin Rabbitt, a seasoned executive with exits to Crestview Partners and Carlyle Group, and backed by a board that includes HRH Prince Khaled bin Alwaleed Al Saud, Vesalius has assembled a team built to scale and deliver returns.

The Business Behind the Billion-Dollar Biohacking Boom

If you think Vesalius Longevity Labs is just another supplement company… think again.

This isn’t a protein powder brand with influencer hype.

It’s a precision-based biotech startup built around innovative peptide formulations, forward-thinking wellness protocols, and a celebrity-driven media engine with names like Chris Bumstead (Cbum) and NFL star George Kittle in the front seat.

But the real story?

It’s the platform they’re building — a digital-first wellness and longevity ecosystem targeting one of the most valuable customer segments in the world:

High-income men aged 40–55+ who want to live stronger, longer, and leaner.

This demographic is spending billions each year on hormone optimization, body recomposition, anti-aging stacks, and personalized performance plans. And they’re not looking for a multivitamin.

They want HGH optimization… GLP-1 alternatives… nootropics for mental focus… and scientifically-backed peptide stacks to hack inflammation, sleep, recovery, and body fat.

That’s where Vesalius Longevity Labs enters the market.

What They Actually Do:

- - Peptide Therapeutics: Vesalius works with an impressive roster of leading doctors and healthcare providers (Dr. Matt Cook, Dr. Jonathan Kuo, Dr. Melissa Petersen) to develop customized peptide stacks and injectables that are geared toward supporting personalized wellness goals.¹⁰
  - Remote Optimization Platform: Clients get access to doctors and a private digital portal—powered by Celia Health, the premier platform for concierge telehealth. Patients can instantly connect with a licensed provider, complete a same-day consultation, and receive a full year’s prescription for personalized peptide treatments.
  - Celebrity Amplification: With over 60 million collective followers between Chris Bumstead (Cbum), Gary Brecka, Greenfield, and George Kittle.

This isn’t just a product — it’s a media-fueled, medically-backed, personalized longevity machine with global ambitions.

And now let’s talk comps — because this is where things get really interesting.

Comparative Analysis of Key Players in Peptide Therapeutics and Related Sectors

VLAB comps april 7

Now consider this…

Hims (NYSE: HIMS) has gone from $16 to a high of $72 per share over the past 12 months — by dominating the vanity telehealth space.¹¹ But their pipeline barely scratches the surface of what Vesalius Longevity Labs is building.

Vesalius isn’t treating hair loss or ED.

They’re equipping doctors with full-body wellness solutions and personalized peptide formulations—all while backed by a science board that would make Harvard jealous.

LifeMD (NASDAQ: LFMD)?

It’s a smaller play, but shows what a focused D2C platform can do in the concierge space. And it’s starting to gain attention as the next speculative mover.

That’s the wave Vesalius Longevity Labs is surfing right now.

But unlike these comps?

They’re bringing an expert science advisory board with deep experience across clinical and wellness disciplines, a tech-first concierge platform, and massive influencer firepower all under one roof.

Now add this to the picture:

Novo Nordisk (NYSE: NVO) — the $300 billion pharmaceutical titan — didn’t become Europe’s most valuable company by accident.

Their peptide-based GLP-1 treatments have completely transformed the obesity and diabetes market.

In doing so, they’ve turned peptides into a household term… and a $42 billion+ revenue machine.¹²

Why It Matters Now

h234bn

- - The longevity biotech market is set to surpass $77.7 billion by 2030.¹³
  - GLP-1 treatments are already creating a $157.5B+ gold rush by 2035.¹⁴
  - The peptide market alone is forecasted to hit $117B by 2034.¹⁵

Vesalius Longevity Labs isn’t just tapping into these trends.

They’re building the only platform that merges all of them — with media power, elite science, and real commercial traction.

Novo Nordisk is a slow-moving behemoth. They’re not built to move fast or pivot into consumer-first, concierge longevity platforms.

Vesalius is.

This is what early-stage investing looks like… right before the crowd catches on.

They’re tapping into the same peptide goldmine, but with the speed, personalization, and branding that can only come from a nimble, D2C biotech.

If Novo proved peptides are worth hundreds of billions…

Vesalius is proving they can be democratized — and delivered directly to the consumer in ways Big Pharma can’t touch.

That’s why this moment matters.

Because investors who saw Novo early potentially made fortunes.

And right now, Vesalius Longevity Labs may be sitting at a similar inflection point—just in a leaner, faster, next-gen form.

A Revenue Machine in a White-Hot Market

Vesalius Longevity Labs isn’t chasing trends. It’s creating a global revenue engine around what could become the next major health breakthrough: peptides.

This isn’t a single-product play.

Vesalius is already generating revenue from:

- - Branded injectable peptides, patches, sprays, and bioregulators
  - White-label deals with wellness clinics and medical distributors
  - Strategic partnerships to co-develop proprietary formulations
  - A global network of physicians driving prescriptions and repeat orders

Early traction is coming from North America, Europe, and the Middle East — but that’s just the beginning. Plans are already in motion to expand into Asia-Pacific and Latin America, where demand for advanced wellness and anti-aging solutions is skyrocketing.

The Advantage Wall: Why Vesalius Is Built to Win

In biotech, scale matters. So does trust. Vesalius Longevity Labs is building both.

Here’s what sets it apart:

- - Physician-led sales model built around real medical needs
  - Exclusive manufacturing tech for cost-efficient, scalable production
  - Proprietary ordering and distribution systems to control quality and speed
  - Global reach with products ready to ship through a multi-region logistics network
  - Relentless R&D pipeline backed by a strong focus on physician education

That’s how you build a moat in a crowded market — and Vesalius Longevity Labs is doing it early.

Let’s Talk Stock: The Numbers Wall Street Doesn’t Know Yet

Now here’s where things get even more interesting…

Because while names like Hims (NYSE: HIMS) and LifeMD (NASDAQ: LFMD) have already taken their stories public — commanding billions and hundreds of millions in market cap — Vesalius Longevity Labs is still private.

But not for long.

This isn’t some bloated unicorn looking for a down round. Vesalius is coming to market lean and tight.

Let that sink in.

A science-backed, influencer-fueled, tech-driven peptide + longevity platform — tapping into multi-trillion-dollar megatrends like:

- - Anti-aging
  - Personalized medicine
  - Concierge bio-optimization
  - And direct-to-consumer digital health

… and it’s about to hit the public market with a fraction of the valuation its comps command.

Hims is worth $8.09B.

LifeMD is trading around $260M.

Even small biotech and medtech names with less traction and weaker teams are going public at $100M+ valuations.

Yet Vesalius Longevity Labs is expected to come in much lower than that — and that’s before the world knows the Saudi royal, the celebrity influencers, the scientific dream team, and the AI-driven delivery system behind it.

Meet the Team Turning Science Fiction Into Shareholder Value

If you want to bet on the future of longevity and peptides…

You don’t just bet on science.

You bet on the people building the machine — those who’ve already taken companies to the finish line, closed billion-dollar deals, scaled health platforms, and captured audiences in the hundreds of millions.

And Vesalius Longevity Labs has assembled a team that’s frankly shocking for a company at this stage.

This is the kind of leadership normally reserved for post-IPO runs — not a startup on the verge of a breakout raise.

Let’s break down who’s behind the curtain.

Kevin RabbittChief Executive Officer

Kevin Rabbitt isn’t your typical wellness startup CEO. He’s a seasoned operator with a private equity playbook and a record of transforming companies into global brands.

Former CEO of Hornblower Group — a global experiential travel brand backed by Crestview Partners
Led NEP Group, a media production powerhouse, through a massive sale to Carlyle Group
Past leadership at TPG-owned 3 Day Blinds and GES, one of the world’s largest tradeshow and events firms
Consulting pedigree from Bain & Company and Deloitte
Now serves on the boards of OneMagnify and Congruex

Rabbitt doesn’t just scale companies — he scales returns. And now he’s building his next multi-billion-dollar success story with Vesalius.

Dr. Matt Cook, (DR., MD, FAARM, ABAARM) Scientific Advisor

If there’s one name in regenerative medicine that’s feared by aging and loved by elite patients… It’s Dr. Matt Cook.

Founder of BioReset® Medical, Dr. Cook has pioneered a multimodal, cellular-level treatment philosophy that’s light years ahead of what your average MD even understands.

20+ years of clinical experience
Global educator in regenerative and functional medicine
Consulted on cutting-edge protocols now being adopted across elite concierge clinics

Vesalius isn’t just using off-the-shelf ideas — they’re bringing in the man creating the playbook.

Gary BreckaStrategic Advisor

Gary isn’t just a biohacker.

He’s a human performance brand with over 16 million monthly impressions and over 1 billion social media views, reflecting a substantial global audience.¹⁶

Founder of The Ultimate Human and co-founder of 10X Health
Trusted by the likes of Joe Rogan, Mark Zuckerberg, and UFC President Dana White
Host of one of the most downloaded podcasts in the longevity space

When Gary talks, audiences buy — and Vesalius Longevity Labs is now the only platform with direct access to that megaphone.

Prince Khaled bin Alwaleed Al SaudBoard Director

Born in California, raised in Riyadh, and trained under the billionaire investing legacy of HRH Prince Alwaleed bin Talal…

Prince Khaled brings an unbeatable trifecta: global credibility, elite capital connections, and deep conviction in longevity tech.

Founder & CEO of KBW Ventures
Executive Vice Chairman & Co-Founder of Arada, a major UAE real estate developer
Vocal advocate for healthtech, clean energy, and disruptive innovation

Having a Saudi royal on your board isn’t just for optics. It opens doors to sovereign capital, elite partnerships, and global expansion.

Strategic Advisors Built for Mass Influence

Ben Greenfield – Biohacking legend. NYT bestselling author. Trusted advisor to pro athletes, C-suite execs, and high-performers worldwide.

Chris Bumstead (“Cbum”) – 6x Mr. Olympia Classic Physique champion. Fitness icon with brand reach into Gymshark, Raw Nutrition, and a loyal audience of millions.

George Kittle – NFL superstar and founder of Tight End University. Known for dominating defenses — and now helping Vesalius dominate the D2C fitness space.

This team isn’t just credible — they’re bankable.

They’ve built empires, sold companies, attracted cult followings, and now they’re laser-focused on making Vesalius the next legendary name in healthspan, peptides, and performance.

Investors are watching for signals.

This team is the signal.

The Window Is Narrow. The Opportunity Is Incredible.

Every so often, a private company emerges with all the signals of a breakout public success.

Vesalius is that company.

It has the hallmarks of a future market leader: a seasoned CEO with a private equity background and multiple successful exits… a science board stacked with globally recognized leaders in regenerative medicine… a concierge delivery model tailored for the booming longevity and bio-optimization market… and a powerful network of high-impact influencers already mobilizing a health-conscious, high-spending audience.

But what sets Vesalius Longevity Labs apart is its timing.

This isn’t a company building for the future — it’s built for right now.

With the peptide market accelerating, and giants like Novo Nordisk validating the space with multibillion-dollar investments, Vesalius is positioned to lead the next wave of innovation.

Investors are getting a rare chance to stake a position in a company before it hits the public markets.

And when it does?

It won’t be a quiet debut.

The stage is already being set. High-profile board members. Massive earned media. A D2C platform with viral potential. And a mission that resonates with millions.

This is what early looks like.

Those who recognize the signals now could be first in line when Vesalius Longevity Labs steps onto the public stage.

Disclaimer

QUICK LINKS TO PREFERRED BROKERAGES

footnotes:
[1] https://pmc.ncbi.nlm.nih.gov/articles/PMC1122833/ [2] https://www.futuremarketinsights.com/reports/peptide-therapeutics-market [3] https://www.financecharts.com/stocks/HIMS [4] https://beautymatter.com/articles/hims-raises-another-50-million? [5] https://forgeglobal.com/hims_ipo/ [6] https://www.financecharts.com/stocks/HIMS [7] https://www.futuremarketinsights.com/reports/peptide-therapeutics-market [8] https://www.vesaliuslabs.com/our-team/hrh-prince-khaled-bin-alwaleed-bin-talal-al-saud [9] https://www.futuremarketinsights.com/reports/peptide-therapeutics-market [10] https://www.vesaliuslabs.com/insights/sweet-earth-announcement [11] https://finance.yahoo.com/quote/HIMS/ [12] https://www.novonordisk-us.com/media/news-archive/news-details.html?id=915256 [13] https://tinyurl.com/ym9dhksf [14] https://tinyurl.com/mva79aux [15] https://www.futuremarketinsights.com/reports/peptide-therapeutics-market [16] https://www.garybrecka.com/

Disclosure:

1) The author of the Article, or members of the author’s immediate household or family, do not own any securities of the companies set forth in this Article. The author determined which companies would be included in this article based on research and understanding of the sector.

2) The Article was issued on behalf of and sponsored by, Vesalius Longevity Labs, Inc. Market Jar Media Inc. has or expects to receive from Vesalius Longevity Labs, Inc.’s Digital Marketing Agency of Record (Native Ads Inc.) up to one hundred twenty one thousand and five hundred and ninety US dollars for a duration of up to twelve (12) months or until budget exhaustion as dictated by Vesalius Longevity Labs, Inc.

3) Statements and opinions expressed are the opinions of the author and not Market Jar Media Inc., its directors or officers. The author is wholly responsible for the validity of the statements. The author was not paid by Market Jar Media Inc. for this Article. Market Jar Media Inc. was not paid by the author to publish or syndicate this Article. Market Jar has not independently verified or otherwise investigated all such information. None of Market Jar or any of their respective affiliates, guarantee the accuracy or completeness of any such information. The information provided above is for informational purposes only and is not a recommendation to buy or sell any security. Market Jar Media Inc. requires contributing authors to disclose any shareholdings in, or economic relationships with, companies that they write about. Market Jar Media Inc. relies upon the authors to accurately provide this information and Market Jar Media Inc. has no means of verifying its accuracy.

4) The Article does not constitute investment advice. All investments carry risk and each reader is encouraged to consult with his or her individual financial professional. Any action a reader takes as a result of the information presented here is his or her own responsibility. By opening this page, each reader accepts and agrees to Market Jar Media Inc.'s terms of use and full legal disclaimer as set forth here. This Article is not a solicitation for investment. Market Jar Media Inc. does not render general or specific investment advice and the information on tradingwhisperer.com should not be considered a recommendation to buy or sell any security. Market Jar Media Inc. does not endorse or recommend the business, products, services or securities of any company mentioned on tradingwhisperer.com.

5) Market Jar Media Inc. and its respective directors, officers and employees hold no shares for any company mentioned in the Article.

6) This document contains forward-looking information and forward-looking statements within the meaning of applicable Canadian and United States securities legislation, (collectively, “forward-looking statements”), which reflect management's expectations regarding Vesalius Longevity Labs, Inc.’s future growth, future business plans and opportunities, expected activities, and other statements about future events, results or performance. Wherever possible, words such as “predicts”, “projects”, “targets”, “plans”, “expects”, “does not expect”, “budget”, “scheduled”, “estimates”, “forecasts”, “anticipate” or “does not anticipate”, “believe”, “intend” and similar expressions or statements that certain actions, events or results “may”, “could”, “would”, “might” or “will” be taken, occur or be achieved, or the negative or grammatical variation thereof or other variations thereof, or comparable terminology have been used to identify forward-looking statements. These forward-looking statements include, among other things, statements relating to: (a) revenue generating potential with respect to Vesalius Longevity Labs, Inc.’s industry; (b) market opportunity; (c) Vesalius Longevity Labs, Inc.’s business plans and strategies; (d) services that Vesalius Longevity Labs, Inc. intends to offer; (e) Vesalius Longevity Labs, Inc.’s milestone projections and targets; (f) Vesalius Longevity Labs, Inc.’s expectations regarding receipt of approval for regulatory applications; (g) Vesalius Longevity Labs, Inc.’s intentions to expand into other jurisdictions including the timeline expectations relating to those expansion plans; and (h) Vesalius Longevity Labs, Inc.’s expectations with regarding its ability to deliver shareholder value. Forward-looking statements are not a guarantee of future performance and are based upon a number of estimates and assumptions of management in light of management’s experience and perception of trends, current conditions and expected developments, as well as other factors that management believes to be relevant and reasonable in the circumstances, as of the date of this document including, without limitation, assumptions about: (a) the ability to raise any necessary additional capital on reasonable terms to execute Vesalius Longevity Labs, Inc.’s business plan; (b) that general business and economic conditions will not change in a material adverse manner; (c) Vesalius Longevity Labs, Inc.’s ability to procure equipment and operating supplies in sufficient quantities and on a timely basis; (d) Vesalius Longevity Labs, Inc.’s ability to enter into contractual arrangements with additional parties; (e) the accuracy of budgeted costs and expenditures; (f) Vesalius Longevity Labs, Inc.’s ability to attract and retain skilled personnel; (g) political and regulatory stability; (h) the receipt of governmental, regulatory and third-party approvals, licenses and permits on favorable terms; (i) changes in applicable legislation; (j) stability in financial and capital markets; and (k) expectations regarding the level of disruption to as a result of CV-19. Such forward-looking information involves a variety of known and unknown risks, uncertainties and other factors which may cause the actual plans, intentions, activities, results, performance or achievements of Vesalius Longevity Labs, Inc. to be materially different from any future plans, intentions, activities, results, performance or achievements expressed or implied by such forward-looking statements. Such risks include, without limitation: (a) Vesalius Longevity Labs, Inc.’s operations could be adversely affected by possible future government legislation, policies and controls or by changes in applicable laws and regulations; (b) public health crises such as CV-19 may adversely impact Vesalius Longevity Labs, Inc.’s business; (c) the volatility of global capital markets; (d) political instability and changes to the regulations governing Vesalius Longevity Labs, Inc.’s business operations (e) Vesalius Longevity Labs, Inc. may be unable to implement its growth strategy; and (f) increased competition.

Except as required by law, Vesalius Longevity Labs, Inc. undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future event or otherwise, after the date on which the statements are made or to reflect the occurrence of unanticipated events. Neither does Vesalius Longevity Labs, Inc. nor any of its representatives make any representation or warranty, express or implied, as to the accuracy, sufficiency or completeness of the information in this document. Neither Vesalius Longevity Labs, Inc. nor any of its representatives shall have any liability whatsoever, under contract, tort, trust or otherwise, to you or any person resulting from the use of the information in this document by you or any of your representatives or for omissions from the information in this document.

7) Any graphs, tables or other information demonstrating the historical performance or current or historical attributes of Vesalius Longevity Labs, Inc. or any other entity contained in this document are intended only to illustrate historical performance or current or historical attributes of Vesalius Longevity Labs, Inc. or such entities and are not necessarily indicative of future performance of Vesalius Longevity Labs, Inc. or such entities.

8) Investing is risky. The information provided in this article should not be considered as a substitute for professional financial consultation. Users should be aware that investing in any form carries inherent risks, and as such, there is a possibility of losing some or all of their investment. The value of investments can fluctuate significantly within a short period, and investors must understand that past performance is not indicative of future results. Additionally, users should exercise caution as transactions involving investments may be irreversible, even in cases of fraud or accidental actions. It is crucial to acknowledge that rapidly evolving laws and technical issues can have adverse effects on the usability, transferability, exchangeability, and value of investments. Furthermore, users must be cognizant of potential security risks associated with their investment activities. Individuals are strongly encouraged to conduct thorough research, seek professional advice, and carefully evaluate their risk tolerance before engaging in any investment endeavors. Market Jar Media Inc. is neither an investment adviser nor a broker-dealer. The information presented on the website is provided for informative purposes only and is not to be treated as a recommendation to make any specific investment. No such information on tradingwhisperer.com constitutes advice or a recommendation.

SEARCH FOR AN ARTICLE

Joe Rogan Just Put Big Pharma on Blast… and This Tiny Peptide Company Could Be the Reason Why